Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Imaging Biometrics® Update

28 Nov 2018 07:00

RNS Number : 6455I
IQ-AI Limited
28 November 2018
 

28 November 2018

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics® Update

 

Appointment of a South Korean Distributor

Imaging Biometrics, LLC ("IB") has appointed Korea Motion ISG ("Korea Motion") as its first distributor in South East Asia. Korean Motion will sell IB's full range of diagnostic imaging products in the areas of brain tumor detection using perfusion maps and the monitoring of brain tumor development. These products have been presented to several leading South Korean hospitals over the last few months, generating significant potential sales interest.

David Smith, CEO of Imaging Biometrics commented, "Our South Korean partner recently demonstrated their enthusiasm and competence in the medical software field through the introduction of StoneChecker securing the first commercial order for that product earlier this month. After trialing the full Imaging Biometrics range with several hospitals in recent months we are confident they will repeat this success with our products for detecting and monitoring brain tumors. This latest agreement marks the start of a concerted effort by management to develop global markets for Imaging Biometrics' products, building upon the success we are achieving in the United States."

ISO 13485:2016 Certification

Imaging Biometrics has received ISO 13485:2016 certification for Medical Device and Quality Management Systems. This ISO certification is required for regulatory purposes specific to the medical device industry.

ISO13485:2016 is an internationally recognised quality standard supporting the design, development, manufacture, and distribution of medical devices. To be certified, companies must demonstrate their ability to provide medical devices and services that consistently fulfill customer and regulatory requirements.

IB offers quantitative and highly-accurate solutions for a variety of neurological and other disorders. Over the years, IB has worked closely with leading scientists and clinicians to overcome limitations that affect conventional imaging. Now customisable and streamlined solutions can be seamlessly integrated in any sized healthcare system.

"This certification underscores our company's steadfast commitment of providing high-quality products to our clients," said IB's CEO, David Smith. "Maintaining a world-class quality management system is a key goal of IB, and our clients can feel confident that our quality management system provides a solid framework for how we conduct business,".

IQ-AI Limited (Ticker:IQAI) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.iq-ai.ltd).

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Fungai Ndoro

Tel: 020 7220 9797

 

About Korea Motion ISG

 

Korea ISG has installed and supported MRI/CT 3D processing imaging software in about 120 prominent Korean hospitals for 23 years and is a prominent medical imaging software distribution (sales and service/support) company in South Korea. They are experienced distributors of medical software from other world leading suppliers, with a wide customer base.

 

About Imaging Biometrics

Imaging Biometrics is a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STREAFFXALDPFFF
Date   Source Headline
2nd Sep 20217:00 amRNSBoard Changes
1st Sep 202110:00 amRNSStart of Trading on the OTCQB Venture Market
27th Aug 20219:57 amRNSHalf Yearly Report
11th Jun 20214:41 pmRNSSecond Price Monitoring Extn
11th Jun 20214:36 pmRNSPrice Monitoring Extension
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:05 amRNSSecond Price Monitoring Extn
11th Jun 202111:00 amRNSPrice Monitoring Extension
11th Jun 20218:00 amRNSIQAI Awarded “Gad-Free” Patent
4th Jun 20217:00 amRNSIB Software Chosen by LA County Hospital
19th May 202112:06 pmRNSResult of AGM
27th Apr 20213:27 pmRNSNotice of AGM
20th Apr 202110:21 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:27 amRNSIQAI commits to Phase 1 study
6th Apr 20217:00 amRNSFive Year NCI Award Grant to IB
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20212:05 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 20219:05 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
28th Jan 20217:00 amRNS"Gad Free" Imaging Update
25th Jan 202111:01 amRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSTechnology Portfolio Update
7th Jan 20212:06 pmRNSSecond Price Monitoring Extn
7th Jan 20212:00 pmRNSPrice Monitoring Extension
31st Dec 202012:41 pmRNSSecond Price Monitoring Extn
31st Dec 202012:36 pmRNSPrice Monitoring Extension
31st Dec 202011:00 amRNSPrice Monitoring Extension
10th Dec 202010:41 amRNSDirector Dealing and CLN Conversion - Correction
9th Dec 20202:05 pmRNSSecond Price Monitoring Extn
9th Dec 20202:01 pmRNSPrice Monitoring Extension
9th Dec 20209:02 amRNSDirector Dealing and Conversion of Loan Notes
7th Dec 202011:25 amRNSDirector Dealing
4th Dec 20204:52 pmRNSIssue of shares to Mayo Clinic
3rd Dec 20207:01 amRNSRelease of StoneChecker 20.12
26th Nov 20207:00 amRNSIMAGING BIOMETRICS UPGRADES IB CLINIC™ SOFTWARE
23rd Nov 20204:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20204:36 pmRNSPrice Monitoring Extension
23rd Nov 20202:06 pmRNSSecond Price Monitoring Extn
23rd Nov 20202:00 pmRNSPrice Monitoring Extension
23rd Nov 20201:45 pmRNSLSN Software is now CE Mark Approved
23rd Nov 202011:06 amRNSSecond Price Monitoring Extn
23rd Nov 202011:00 amRNSPrice Monitoring Extension
20th Nov 202011:05 amRNSSecond Price Monitoring Extn
20th Nov 202011:00 amRNSPrice Monitoring Extension
20th Nov 20209:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.